Medisprudence delivers physician-authored medical case intelligence: IME report deconstruction, case viability screening, defense vulnerability analysis, Defense Medical Lens pre-mediation reports, expert readiness briefs, and related intelligence documents. It does not deliver legal advice, legal strategy, damages valuation, expert testimony, expert affidavits, certificates of merit, court appearances, patient care, or independent medical examinations. All work is delivered under attorney direction.
Legal nurse consultants are registered nurses who review medical records and produce chronologies and summaries. That is valuable for extraction and organization. Medisprudence adds the physician interpretation layer — what the organized record means for causation, for the IME response, for the expert, and for the demand. More specifically, Medisprudence’s analysis is built on 3,000+ US payer-side claim reviews under InterQual and MCG — a physician-review background that complements, rather than duplicates, LNC record organization. The analysis is calibrated to how defense reviewers actually evaluate records, not just what the clinical picture shows.
A medical expert witness is a testifying expert — retained for opinion, deposition, and trial. Medisprudence is a non-testifying consulting physician — retained for pre-expert case intelligence before the expert engagement. The two are complementary, not competing: Medisprudence helps you decide whether to retain an expert, which specialty you need, and what documentation must be in place before the expert reviews the file. The cost of Medisprudence is a fraction of most expert retainer entry costs.
The Defense Medical Lens is a physician-authored model of likely medical pressure points, informed by prior payer-side utilization-management work across 3,000+ US claim reviews. It does not claim to predict a particular opponent’s strategy or imply current access to proprietary criteria. The value is the disciplined application of documentation-threshold and medical-necessity experience to the supplied record, which is different from a general chronology or expert-witness referral.
Yes. Medisprudence serves both plaintiff and defense clients under conflict-screened, separate engagements. We do not serve both sides of the same matter. Conflict checks are conducted at intake. Defense and TPA engagements are available for reserve-setting medical exposure analysis, pre-mediation medical review, and WC causation assessment.
It is a physician-authored review of whether the claimed medical special damages are clinically necessary, related to the pleaded injury, coded consistently, and reasonable in amount — combined in one work product rather than split between a billing analyst and a treating physician. For plaintiff teams it substantiates the specials before demand or mediation; for defense, TPAs, and carriers the same method runs as a Billed-Charge Exposure Review identifying unnecessary, unrelated, inflated, miscoded, or duplicative charges before reserve and settlement posture is set. It is delivered as non-testifying, attorney-directed work product.
Six services are built specifically for defense teams, TPAs, and carriers: IME Quality Review (pre-submission physician review of your defense IME before it is served), Plaintiff Expert Report Analysis (analytical deconstruction of the plaintiff's disclosed medical expert report), Medical Reserve Analysis (physician-authored medical exposure assessment for reserve decisions), UR Process Audit (denial defensibility review for bad faith defense), Bellwether Defense Medical Screening (plaintiff pool evaluation for MDL defense coordination), and Medical Charge & Necessity Review (billed-charge exposure: necessity, relatedness, coding, and reasonableness of claimed specials). All existing bilateral services — Defense Medical Lens, Case Viability Screening, Defense Vulnerability Analysis — are also available with defense framing.
Same base rates as plaintiff services. The difference is payment framing: institutional invoice terms (Net 15 or Net 30), no case-cost language, and retainer/volume arrangements available for TPAs and carriers with recurring case flow. Defense engagement is an operating expense, not a case cost advance.
Every inquiry — both plaintiff and defense — includes opposing party identification at intake. The conflict check is completed before scope confirmation. Medisprudence will not serve both sides of the same matter. If a conflict is found, the second inquiry is declined without disclosing which party or matter created the conflict. Every scope confirmation letter includes conflict-check confirmation. Full conflict policy →
No. The first step is deliberately low-friction. You send only general case facts — case type, injury, IME status, approximate record volume, deadline, and the decision you need to make. Do not send PHI by email. Medisprudence confirms scope, pricing, turnaround, and conflict status. BAA and engagement terms are confirmed before any records are transmitted.
Cross-border processing is disclosed before any records are accepted and before engagement is formed. This is a deliberate transparency policy. The BAA executed before engagement governs PHI handling under the cross-border framework. All AI-assisted extraction uses systems covered by appropriate contractual safeguards. PHI is not entered into public consumer AI tools. Records are not used for model training.
AI-assisted extraction is used in Stage 1 of the workflow — capturing dates, providers, diagnoses, procedures, and page references from medical records. This produces structured data, not intelligence. Stage 2 is physician-authored: the reviewing physician checks extracted data against original records and applies all clinical intelligence layers. Every deliverable identifies AI-assisted versus physician-authored components at the component level.
No. Medisprudence does not provide independent expert testimony, expert affidavits, certificates of merit, or court-facing causation opinions. This is by design. The non-testifying consulting role is structurally distinct from the expert-witness role. It supports candid pre-expert analysis and predictable scope, while ordinary conflict screening and work-product rules still apply.
No. Medisprudence provides non-testifying, attorney-directed Medical Charge & Necessity Review. The review evaluates medical necessity, relatedness, coding integrity, and charge reasonableness for case strategy, settlement, reserve, or expert-preparation purposes. When a sworn affidavit or testimony specifically on charges is required, Medisprudence can coordinate with a US-credentialed billing/coding or physician partner where appropriate.
Case Viability Screening (CVA): 72 hours standard. IME Report Deconstruction: 3–5 business days. Defense Medical Lens add-on: 48 hours. Defense Medical Lens standalone: 3–4 days. Full Intelligence Report (CMIP): 5–10 business days depending on record volume. Medical Charge & Necessity Review: 3–5 business days for a leverage memo, 5–10 for a standard review. Priority options may be available and are confirmed at scope; they are not guaranteed.
Case Viability Screening starts at $350. IME Report Deconstruction starts at $500. Defense Medical Lens starts at $400 as an add-on, $950 standalone. Full Intelligence Report (CMIP) starts at $1,500. Medical Charge & Necessity Review starts at $450 for a leverage memo and $1,200 for a standard review. All fees are confirmed at scope. No contingent-fee arrangements are available. Coordinated packages are available from $900 and are invoiced as one scoped engagement. Package value is scope simplicity, not an automatic discount. A firm may classify the expense as a case cost only where its engagement agreement and applicable law permit.
A firm may choose to advance the invoice as a litigation case cost, but that treatment is not universal and Medisprudence does not determine whether it is recoverable from a client or settlement. The firm must apply its engagement agreement, governing law, ethics rules, and the case outcome. Medisprudence is paid according to the confirmed invoice terms; the firm’s internal accounting and any later recovery are separate matters.
For established attorney clients on confirmed retainer arrangements, deferred billing — where the engagement fee is invoiced at case resolution rather than upon delivery — can be discussed at scope confirmation. This is not available for first-time engagements. Contact Medisprudence to discuss whether your firm’s case volume and practice area make a deferred billing arrangement appropriate.
The $350 Case Viability Screening remains available as a tightly defined paid screen and may be credited toward a substantially overlapping larger engagement commissioned within 30 days. New-client substantive reports generally begin at $750. Lower published amounts may apply to tightly controlled report-only work or same-record add-ons.
No. Priority review may be available from a 50% surcharge, but only after record volume, specialty, complete-file status, existing commitments, and quality-control requirements are assessed. Large or weekend-displacing matters may require a higher surcharge or may be declined.
Through a paid representative pilot. Production pricing, file assumptions, escalation rules, quality controls, and a hard monthly capacity cap are agreed only after calibration. Medisprudence does not promise unlimited throughput.
Start with a no-PHI inquiry — describe the case type and the decision you need to make.
Request Case Review Send a Message